- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYPRESS BIOSCIENCE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,21 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| AMYLYX PHARMACEUTICALS | 21,850 | 0,00 % | Amylyx Pharmaceuticals, Inc. - 10-Q, Quarterly Report | ||
| ENLIVEN THERAPEUTICS | 59,70 | 0,00 % | Enliven Therapeutics GAAP EPS of -$0.49 misses by $0.10 | ||
| VERA THERAPEUTICS | 30,380 | +0,10 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TREVI THERAPEUTICS | 18,650 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,170 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,300 | +0,07 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 47,290 | -0,11 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Second Quarter 2026 Financial Results | PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,710 | 0,00 % | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -
- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in... ► Artikel lesen | |
| ERASCA | 18,615 | -0,03 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 318,88 | -0,11 % | Praxis Precision Medicines Q2 2026 Earnings Preview | ||
| BICARA THERAPEUTICS | 25,890 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | ||
| ARCUTIS BIOTHERAPEUTICS | 27,000 | -0,37 % | Arcutis raises 2026 net revenue guidance to $525M-$540M as ZORYVE demand expands and telehealth launches | ||
| CG ONCOLOGY | 72,41 | -0,01 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,080 | +0,04 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen |
CYPRESS BIOSCIENCE INC gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYPRESS BIOSCIENCE INC finden Sie auf Wallstreet Online.